Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Via The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
Where Will AbbVie Be in 5 Years?
Via The Motley Fool
Smart Money Is Betting Big In ABBV Options
Via Benzinga
Seeking Beta
While the “Trump rally” appears to have just begun, one of its initial hallmarks is that investors want beta. 
Via Talk Markets
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. 
Via Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line. 
Via The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
With the loss of Humira’s exclusivity and a recent dip in stock value, many are questioning the future trajectory of AbbVie stock. 
Via Talk Markets
Navigating 14 Analyst Ratings For AbbVie
Via Benzinga
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. 
Via Talk Markets
This Is What Whales Are Betting On AbbVie
Via Benzinga
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3. 
Via Benzinga
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records. 
Via The Motley Fool
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
My Favorite Dividend King to Buy in November
This Dividend King truly wears the crown. 
Via The Motley Fool
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AbbVie Stock Was Getting Mashed on Monday
A splashy recent acquisition by the company might not be panning out. 
Via The Motley Fool
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet... 
Via Benzinga
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline. 
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps. 
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies. 
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.